Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.
Rachel H. McMahan,Xiaoxin X. Wang,Lin Ling Cheng,Tibor I. Krisko,Maxwell L. Smith,Karim C. El Kasmi,Mark Pruzanski,Luciano Adorini,Lucy Golden-Mason,Lucy Golden-Mason,Moshe Levi,Hugo R. Rosen,Hugo R. Rosen +12 more
TLDR
Treatment of a murine model of nonalcoholic fatty liver disease with a dual FXR/TGR5 agonist decreased intrahepatic inflammation and altered the immune phenotype of monocytes and macrophages, indicating potential targeting strategies for treatment of NAFLD.About:
This article is published in Journal of Biological Chemistry.The article was published on 2013-04-26 and is currently open access. It has received 183 citations till now. The article focuses on the topics: G protein-coupled bile acid receptor & Farnesoid X receptor.read more
Citations
More filters
Journal ArticleDOI
Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.
TL;DR: The mechanistic links between bile acids and gastrointestinal carcinogenesis in CRC and HCC are discussed, which involve two major bile acid-sensing receptors, farnesoid X receptor (FXR) and G protein-coupled bile Acid receptor 1 (TGR5).
Journal ArticleDOI
Bile Acid Signaling in Metabolic Disease and Drug Therapy
Tiangang Li,John Y.L. Chiang +1 more
TL;DR: An interaction of liver bile acids and gut microbiota in the regulation of liver metabolism and potential therapeutic agents for treating metabolic diseases of the liver are revealed.
Journal ArticleDOI
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Konstantin Kazankov,Simon Mark Dahl Jørgensen,Karen Louise Thomsen,Holger Jon Møller,Hendrik Vilstrup,Jacob George,Detlef Schuppan,Detlef Schuppan,Henning Grønbæk +8 more
TL;DR: Experimental and clinical data support a central role for macrophages in the development and progression of nonalcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH) and studies investigating drugs that target macrophage recruitment to the liver, Macrophage polarization and their inflammatory effects as potential treatment options for patients with NASH are reviewed.
Journal ArticleDOI
Current and future pharmacological therapies for NAFLD/NASH
Yoshio Sumida,Masashi Yoneda +1 more
TL;DR: Among a variety of medications in development, four agents such as OCA, elafibranor, ASK1 inhibitor, and CVC are currently being evaluated in an international phase 3 trial for the treatment of NASH.
Journal ArticleDOI
Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
TL;DR: Current available data on the relationships of bile acids to NAFLD and the potential for therapeutically targeting bile‐acid‐related pathways to address this growing world‐wide disease are summarized.
References
More filters
Journal ArticleDOI
Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method
TL;DR: The 2-Delta Delta C(T) method as mentioned in this paper was proposed to analyze the relative changes in gene expression from real-time quantitative PCR experiments, and it has been shown to be useful in the analysis of realtime, quantitative PCR data.
Journal ArticleDOI
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
David E. Kleiner,Elizabeth M. Brunt,Mark L. Van Natta,Cynthia Behling,Melissa J. Contos,Oscar W. Cummings,Linda D. Ferrell,Yao Chang Liu,Michael Torbenson,Aynur Unalp-Arida,Matthew M. Yeh,Arthur J. McCullough,Arun J. Sanyal +12 more
TL;DR: A strong scoring system and NAS for NAFLD and NASH with reasonable inter‐rater reproducibility that should be useful for studies of both adults and children with any degree ofNAFLD are presented.
Journal ArticleDOI
Alternative activation of macrophages
TL;DR: The evidence in favour of alternative macrophage activation by the TH2-type cytokines interleukin-4 (IL-4) and IL-13 is assessed, and its limits and relevance to a range of immune and inflammatory conditions are defined.
Journal ArticleDOI
Nonalcoholic fatty liver disease.
TL;DR: Nonalcoholic fatty liver disease is associated with an increased risk of all-cause death, probably because of complications of insulin resistance such as vascular disease, as well as due to cirrhosis and hepatocellular carcinoma, which occurs in a minority of patients.
Journal ArticleDOI
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
TL;DR: Diet-induced obesity leads to a shift in the activation state of ATMs from an M2-polarized state in lean animals that may protect adipocytes from inflammation to an M1 proinflammatory state that contributes to insulin resistance.
Related Papers (5)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Charles Thomas,Antimo Gioiello,Lilia G. Noriega,Lilia G. Noriega,Axelle Strehle,Julien Oury,Giovanni Rizzo,Antonio Macchiarulo,Hiroyasu Yamamoto,Hiroyasu Yamamoto,Chikage Mataki,Chikage Mataki,Mark Pruzanski,Roberto Pellicciari,Johan Auwerx,Johan Auwerx,Kristina Schoonjans,Kristina Schoonjans +17 more